You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
FDA accepts sNDA for MR-141 for the treatment of presbyopia
Login
Username:

Password:


Related Headlines

Xcovery and EVERSANA partner for US commmercialisation of lung cancer drug Ensacove

Jazz Pharmaceuticals reports FDA acceptance and Priority Review of sBLA for Ziihera (zanidatamab-hrii) combinations in first-line HER2+ locally advanced or metastatic GEA

Novartis secures European approval for remibrutinib in chronic spontaneous urticaria

Evofem signs exclusive deal to expand SOLOSEC distribution in sub-Saharan Africa

GSK secures US and EU fast-track designations for efimosfermin in MASH

AstraZeneca secures US approval for Saphnelo self-administration in lupus treatment

Abbott presents late-breaking clinical data on treating heart rhythm disorders

Novartis receives positive CHMP opinion for Itvisma in spinal muscular atrophy

Servier completes Day One Biopharmaceuticals acquisition

Cipla's AB-rated Ventolin HFA generic receives US FDA approval

FDA expands Sanofi and Regeneron's Dupixent approval to younger children with chronic spontaneous urticaria

WuXi Biologics gains MFDS approval for three Wuxi manufacturing sites

OrganaBio and RxMP Therapeutics partner to advance RMP-402 haemostatic drug product

Thryv Therapeutics doses first patients in Wave II clinical study for Long QT Syndrome; THRV-1268 receives FDA Fast Track Designation

WuXi Biologics receives South Korean certification for commercial manufacturing of bispecific antibody therapeutics

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026